Diaceutics (LON:DXRX) Stock Price Up 9.4% – Time to Buy?

Diaceutics PLC (LON:DXRX) shares were up 9.4% during trading on Tuesday . The company traded as high as GBX 186.90 and last traded at GBX 186. 1,307,491 shares changed hands during mid-day trading, an increase of 546% from the average session volume of 202,378 shares. The stock had previously closed at GBX 170.

Analyst Ratings Changes

Separately, Canaccord Genuity Group reissued a “buy” rating and issued a GBX 215 price target on shares of Diaceutics in a report on Tuesday. Two equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Diaceutics has an average rating of “Buy” and an average target price of GBX 215.

Diaceutics Price Performance

The company has a quick ratio of 9.92, a current ratio of 3.43 and a debt-to-equity ratio of 2.85. The firm has a market capitalization of £157.84 million, a PE ratio of 1,690.91 and a beta of 0.88. The stock has a 50-day moving average price of GBX 145.09 and a 200 day moving average price of GBX 150.64.

Diaceutics (LON:DXRX) last released its quarterly earnings results on Tuesday, September 22nd. The company reported GBX (3.27) earnings per share (EPS) for the quarter. Diaceutics had a net margin of 0.25% and a return on equity of 0.25%. Equities analysts forecast that Diaceutics PLC will post 1.0107919 EPS for the current fiscal year.

Diaceutics Company Profile

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world’s leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX – The Diagnostics Network®.